Dengue Vaccine Now Available In Indonesia
The world’s first vaccine against the dangerous dengue fever is now available at clinics and private hospitals in Indonesia. The vaccine was produced and launched by Sanofi Pasteur, a multinational pharmaceutical company that specializes in the production of vaccines; it has also been approved by the Indonesian Drug and Food Regulation Agency (BPOM) for children aged 9 to 16 years as a precaution against the 4 serotypes of dengue fever.
There has been a recent dramatic 17% increase in dengue fever recently, which is a form of hemorrhagic fever that is transmitted via the bite of the Aedes mosquito. In 2015, a total of 129,000 cases of DBD were recorded in Indonesia in 2015, a number that is seen to be increasing in 2016.
Results have shown that the new vaccine is capable of preventing high hospitalization rates associated with DBD with a period of effectiveness of up to four years.
The use of the vaccine has now been initially approved in 12 countries: Mexico, Peru, Indonesia, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Thailand, Singapore, and Bolivia.